Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Time to Market for H2S Pipeline

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Oct 16, 2021 3:37pm

161 Views

Post# 34013786

RE:RE:RE:RE:RE:RE:RE:RE:Time to Market for H2S Pipeline

I doubt they would go with dosing regimen (Q8H) as part of their differentiation strategy was being "a once a day pill".

Ill say that their research into selecting a different moiety besides TBZ will be a major factor in keeping that OD differentiation.

mstrmnd wrote: Yes, completely agree. This was briefly discussed at the AGM as well by Stauffer although at that time awaiting biomarker confirmation.

150 mg x 90 days will not work due to p450 inhibition. Loading could work although challenging for OTC marketing.

150 mg x 14 days works despite p450 inhibition, both safe and effective, hence new strategy.

The answer for chronic use could be as simple as 75 mg x 14 days (25 mg tabs every 8 hours) and then 25 mg daily x 90 days, as you say. Trial should allow for dose reduction on upon LTE prior to discontinuation.

Rawrasaurus wrote:
Mstrmind, I'll look it up but there is parti cyp 450 inhibition. I mentioned it in ceo but I believe it is the c9 pathway (don't quote me til I find the study). It almost certainly is building up due to his inhibition, but can also almost certainly be corrected by dropping the dose and requiring a longer ramp up time before we see clinical significance. From a clinical use, I could see this requiring a loading dose for a few days to a week before the dose gets dropped back to a low once daily dose to maintain serum levels.